<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627728</url>
  </required_header>
  <id_info>
    <org_study_id>GOIRC-05-2016</org_study_id>
    <nct_id>NCT03627728</nct_id>
  </id_info>
  <brief_title>Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer</brief_title>
  <acronym>a-MANTRA</acronym>
  <official_title>Phase II Randomized Study of Maintenance Regorafenib vs Placebo in no Progression Patients After First-line Platinum and Fluoropyrimidines Based Chemotherapy in HER2 Negative Locally Advanced/Metastatic Gastric or Gastroesophagel Junction Cancer (a-MANTRA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Oncologico Italiano di Ricerca Clinica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Oncologico Italiano di Ricerca Clinica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled, multicenter Phase-II study.&#xD;
&#xD;
      Approximately 120 subjects with CR/PR/SD after platinum compounds and fluoropyrimidines based&#xD;
      regimens: up to 6 cycles of cisplatin and 5-fluorouracil or capecitabine, up to 12 cycles of&#xD;
      FOLFOX, up to 8 cycles of XELOX, will be randomly assigned (1:1 ratio) to one of the&#xD;
      following treatment groups:&#xD;
&#xD;
      Arm A: Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or&#xD;
      progression disease Arm B: Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4&#xD;
      weeks, until intolerance or progression disease Primary Variable: PFS1&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS1</measure>
    <time_frame>36 months</time_frame>
    <description>Progression free survival will be calculated for all patients from the date of randomization until the date PD or death is first reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>36 months</time_frame>
    <description>time from date of randomization to the date of Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS2</measure>
    <time_frame>36 months</time_frame>
    <description>PFS 2 will be calculated from the start of second line therapy to PD or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability</measure>
    <time_frame>36 months</time_frame>
    <description>The overall incidences of AEs will be summarized. Patients who experienced the same event on more than one occasion are counted only once in the calculation of the event frequency, at the highest intensity ever observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>36 months</time_frame>
    <description>in patients who are randomized at enrollment to treatment with regorafenib vs placebo,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life To compare the patient treatment-related symptoms</measure>
    <time_frame>up to 8 months</time_frame>
    <description>To compare the patient treatment-related symptoms as measured by the European Organization for research and treatment of cancer EORTC QLQ-C30, (days 1, week , 8, 16, 24, 32) , for patients in each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biomarker evaluation</measure>
    <time_frame>36 months</time_frame>
    <description>To correlate the genetic mutational profile of the tumors with the RR and the OS of the patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>regorafenib/placebo</description>
    <arm_group_label>regorafenib</arm_group_label>
    <other_name>stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>regorafenib/placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male of female ≥ 18 years of age&#xD;
&#xD;
          2. Have an Eastern Cooperative Oncology Group performance status of 0 or 1 within 14 days&#xD;
             prior to the initiation of study treatment&#xD;
&#xD;
          3. Diagnosis of histologically confirmed adenocarcinoma of the stomach or&#xD;
             gastroesophageal junction&#xD;
&#xD;
          4. HER2 negative gastric or gastroesophagel junction cancer ( ICH 0, IHC 1+, IHC + FISH&#xD;
             -)&#xD;
&#xD;
          5. Locally advanced/metastatic gastric or gastroesophageal junction cancer&#xD;
&#xD;
          6. CR/PR/SD after first-line platinum compound and Fluoropyrimidines based chemotherapy&#xD;
&#xD;
          7. Measurable disease according to RECIST 1.1 criteria&#xD;
&#xD;
          8. Have adequate bone marrow function, liver function, and renal function, as measured by&#xD;
             the following laboratory assessments conducted within 7 days prior to the initiation&#xD;
             of study treatment:&#xD;
&#xD;
          9. Total bilirubin 1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
         10. Alanine aminotransferase and aspartate aminotransferase 3 times the ULN&#xD;
&#xD;
         11. Lipase 1.5 times the ULN&#xD;
&#xD;
         12. Serum creatinine 1.5 times the ULN&#xD;
&#xD;
         13. Glomerular filtration rate 30 mL/min/1,73 m2 according to the Modified Diet in Renal&#xD;
             Disease abbreviated formula&#xD;
&#xD;
         14. International normalized ratio of prothrombin time and activated partial&#xD;
             thromboplastin time 1.5 times the ULN. Subjects who are therapeutically treated with&#xD;
             an agent such as warfarin or heparin will be allowed to participate if no underlying&#xD;
             abnormality in coagulation parameters exists per medical history.&#xD;
&#xD;
         15. Platelet count 100,000 /mm3, hemoglobin 9 g/dL, absolute neutrophil count 1500/mm3&#xD;
             without transfusions or granulocyte colony stimulating factor and other hematopoietic&#xD;
             growth factors&#xD;
&#xD;
         16. Alkaline phosphatase ≤ 2.5 times the ULN&#xD;
&#xD;
         17. Understand, be willing to give consent, and sign the written informed consent form&#xD;
             (ICF) prior to undergoing any study-specific procedure.&#xD;
&#xD;
         18. If female and of childbearing potential, have a negative result on a pregnancy test&#xD;
             performed a maximum of 7 days before initiation of study treatment.&#xD;
&#xD;
         19. If female and of childbearing potential, or if male, agree to use adequate&#xD;
             contraception (eg, abstinence, intrauterine device, oral contraceptive, or&#xD;
             double-barrier method) based on the judgment of the investigator or a designated&#xD;
             associate from the date on which the ICF is signed until 8 weeks after the last dose&#xD;
             of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir,&#xD;
             itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir,&#xD;
             saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine,&#xD;
             phenobarbital, phenytoin, rifampin, St. John's Wort)&#xD;
&#xD;
          2. Have used biologic response modifiers, such as G-CSF, within 3 weeks of study entry&#xD;
&#xD;
          3. Have had prior treatment with regorafenib or any other VEGFR-targeting kinase&#xD;
             inhibitor.&#xD;
&#xD;
          4. Completed their last dose of chemotherapy more than 8 weeks, whichever came later,&#xD;
             prior to randomization.&#xD;
&#xD;
          5. Have had prior or concurrent cancer distinct in primary site or histology from GC or&#xD;
             GJC within 5 years prior to randomization EXCEPT for curatively treated cervical&#xD;
             cancer in situ, no-melanoma skin cancer, or superficial bladder tumors classified as&#xD;
             noninvasive tumor (Ta), carcinoma in situ (Tis), or tumor invades lamina propria (T1).&#xD;
&#xD;
          6. Have had systemic anticancer therapy including cytotoxic therapy, signal transduction&#xD;
             inhibitors, immunotherapy, and/or hormonal therapy within 4 weeks prior to initiation&#xD;
             of study treatment.&#xD;
&#xD;
          7. Have unresolved toxicity higher than National Cancer Institute-Common Terminology for&#xD;
             Adverse Events version 4.0 (NCI-CTCAE v 4.0) Grade 1 attributed to any prior&#xD;
             therapy/procedure, excluding alopecia and/or oxaliplatin-induced neurotoxicity ≤ Grade&#xD;
             2 and hemoglobin ≥ 9 g/dL as per inclusion criteria&#xD;
&#xD;
          8. Have had a major surgical procedure, open biopsy, or significant traumatic injury&#xD;
             within 28 days prior to initiation of study treatment.&#xD;
&#xD;
          9. Are pregnant.&#xD;
&#xD;
         10. Are breastfeeding.&#xD;
&#xD;
         11. Are unable to swallow oral tablets (crushing of study treatment tablets is not&#xD;
             allowed).&#xD;
&#xD;
         12. Have congestive heart failure classified as New York Heart Association Class 2 or&#xD;
             higher&#xD;
&#xD;
         13. Have had unstable angina (angina symptoms at rest) or new-onset angina 3 months prior&#xD;
             to screening.&#xD;
&#xD;
         14. Have had a myocardial infarction 6 months prior to initiation of study treatment.&#xD;
&#xD;
         15. Have cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta&#xD;
             blockers or digoxin.&#xD;
&#xD;
         16. Have uncontrolled hypertension (systolic blood pressure [SBP] 140 mmHg or diastolic&#xD;
             blood pressure [DBP] 90 mmHg) despite optimal medical management.&#xD;
&#xD;
         17. Have had arterial or venous thrombotic or embolic events such as cerebrovascular&#xD;
             accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary&#xD;
             embolism within 6 months prior to the initiation of study treatment.&#xD;
&#xD;
         18. Have an ongoing infection with severity of Grade 2 or above (NCI-CTCAE v 4.0).&#xD;
&#xD;
         19. Have a known history of human immunodeficiency virus infection.&#xD;
&#xD;
         20. Have either active or chronic hepatitis B or C requiring treatment with antiviral&#xD;
             therapy.&#xD;
&#xD;
         21. Have a seizure disorder requiring medication.&#xD;
&#xD;
         22. Have a history of organ allograft.&#xD;
&#xD;
         23. Have evidence or history of any bleeding diathesis (including mild hemophilia),&#xD;
             irrespective of severity.&#xD;
&#xD;
         24. Have had a hemorrhage or a bleeding event Grade 3 (NCI-CTCAE v 4.0) within 4 weeks&#xD;
             prior to the initiation of study treatment.&#xD;
&#xD;
         25. Have a nonhealing wound, ulcer, or bone fracture.&#xD;
&#xD;
         26. Have renal failure requiring hemodialysis or peritoneal dialysis.&#xD;
&#xD;
         27. Have dehydration Grade 1 (NCI-CTCAE v 4.0).&#xD;
&#xD;
         28. Have interstitial lung disease with ongoing signs and symptoms at the time informed&#xD;
             consent is obtained.&#xD;
&#xD;
         29. Have persistent proteinuria &gt; 3.5 g/24 hours measured by urine protein creatinine&#xD;
             ratio from a random urine sample (Grade 3, NCI-CTCAE v 4.0).&#xD;
&#xD;
         30. Have any other serious or unstable illness, or medical, psychological, or social&#xD;
             condition, that could jeopardize the safety of the subject and/or his/her compliance&#xD;
             with study procedures, or may interfere with the subject's participation in the study&#xD;
             or evaluation of the study results.&#xD;
&#xD;
         31. Have a known hypersensitivity to any of the study drugs, study drug classes, or&#xD;
             excipients in the formulation of the study drugs.&#xD;
&#xD;
         32. Have any malabsorption condition.&#xD;
&#xD;
         33. Have a close affiliation with the investigational site (eg, be a close relative of the&#xD;
             investigator) or be a dependent person (eg, be an employee or student working at the&#xD;
             investigational site).&#xD;
&#xD;
         34. Untreated gastro-esophageus varices&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmine Pinto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gruppo Oncologico Italiano di Ricerca Clinica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carmine pinto, MD</last_name>
    <phone>+390522296614</phone>
    <email>carmine.pinto@ausl.re.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annalisa Berselli, Biologist</last_name>
    <phone>+390522295181</phone>
    <email>annalisa.berselli@ausl.re.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmine Pinto, MD</last_name>
      <phone>+390522295181</phone>
      <email>carmine.pinto@ausl.re.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

